ICU Medical, Inc. (ICUI)
167.58
+1.29
(+0.78%)
USD |
NASDAQ |
Sep 04, 16:00
167.78
+0.20
(+0.12%)
After-Hours: 20:00
ICU Medical Research and Development Expense (Quarterly) : 22.70M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 22.70M |
| March 31, 2026 | 21.28M |
| December 31, 2025 | 21.09M |
| September 30, 2025 | 21.25M |
| June 30, 2025 | 21.87M |
| March 31, 2025 | 23.29M |
| December 31, 2024 | 22.36M |
| September 30, 2024 | 21.03M |
| June 30, 2024 | 23.39M |
| March 31, 2024 | 21.84M |
| December 31, 2023 | 22.41M |
| September 30, 2023 | 20.87M |
| June 30, 2023 | 22.30M |
| March 31, 2023 | 19.76M |
| December 31, 2022 | 23.45M |
| September 30, 2022 | 23.10M |
| June 30, 2022 | 22.56M |
| March 31, 2022 | 23.87M |
| December 31, 2021 | 13.17M |
| September 30, 2021 | 12.24M |
| June 30, 2021 | 11.38M |
| March 31, 2021 | 10.71M |
| December 31, 2020 | 11.80M |
| September 30, 2020 | 10.13M |
| June 30, 2020 | 10.28M |
| Date | Value |
|---|---|
| March 31, 2020 | 10.75M |
| December 31, 2019 | 12.59M |
| September 30, 2019 | 12.00M |
| June 30, 2019 | 11.20M |
| March 31, 2019 | 12.82M |
| December 31, 2018 | 13.52M |
| September 30, 2018 | 13.18M |
| June 30, 2018 | 13.58M |
| March 31, 2018 | 12.59M |
| December 31, 2017 | 13.88M |
| September 30, 2017 | 12.77M |
| June 30, 2017 | 12.97M |
| March 31, 2017 | 11.64M |
| December 31, 2016 | 2.654M |
| September 30, 2016 | 3.65M |
| June 30, 2016 | 3.338M |
| March 31, 2016 | 3.313M |
| December 31, 2015 | 4.057M |
| September 30, 2015 | 4.227M |
| June 30, 2015 | 3.122M |
| March 31, 2015 | 4.308M |
| December 31, 2014 | 5.08M |
| September 30, 2014 | 5.055M |
| June 30, 2014 | 4.566M |
| March 31, 2014 | 3.631M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Baxter International, Inc. | 125.00M |
| Becton, Dickinson & Co. | 258.00M |
| Boston Scientific Corp. | 554.00M |
| Glaukos Corp. | 51.30M |
| Medline, Inc. | -- |